RIGEL PHARMACEUTICALS INC
RIGLNasdaq
$40.54
↓ -2.7%Jul 17 close · end-of-day
Price
1Y↑ +110.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$798.1M
Enterprise Value
$696.4M
P/E
2.1
P/S
2.7
P/B
2.0
EV/EBITDA
5.5
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$299.8M
Net Income (TTM)
$364.2M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
41.6%
Net Margin
121.5%
ROE
91.1%
ROIC
41.8%
Debt / Equity
0.1
Net Cash
$101.7M
Return 1Y
+114.4%
Company profile
Rigel Pharmaceuticals, Inc. discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the. treatment of warm autoimmune hemolytic anemia.
- CEO
- Raul R. Rodriguez
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 160
- Headquarters
- California
- Website
- rigel.com
Management & directors
- Hannah Alison L.EVP, Chief Medical Officer
- Furey Raymond J.EVP, GC, CCO & Corp Sec
- Rodriguez Raul RCEO, President
- Rojkjaer LisaEVP, Chief Medical Officer
- Santos David AEVP, Chief Commercial Officer
- Schorno Dean LEVP & Chief Financial Officer
Roles derived from SEC Form 4 filings.
Earnings
RIGL Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$58.8M↑ +10.3%
Diluted EPS$0.44↓ -30.2%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $108.6M | $149.2M | $120.2M | $116.9M | $179.3M | $294.3M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$29.0M | -$12.5M | -$55.5M | -$20.5M | $24.2M | $125.5M |
| Net income | -$29.7M | -$17.9M | -$58.6M | -$25.1M | $17.5M | $367.0M |
| Diluted EPS | -$0.18 | -$0.11 | -$3.44 | -$1.44 | $0.99 | $19.48 |
| Operating cash flow | -$52.2M | $5.9M | -$73.8M | -$5.7M | $31.5M | $75.7M |
| Free cash flow | -$53.4M | $5.3M | -$74.2M | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -26.7% | -8.4% | -46.2% | -17.5% | 13.5% | 42.6% |
| Net margin | -27.4% | -12.0% | -48.7% | -21.5% | 9.8% | 124.7% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $36.8M | $55.3M | $57.6M | $53.3M | $101.7M | $69.5M | $69.8M | $58.8M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $447,000.00 | $14.1M | $16.7M | $12.8M | $61.1M | $28.4M | $23.2M | $11.9M |
| Net income | -$1.0M | $12.4M | $14.3M | $11.4M | $59.6M | $27.9M | $268.1M | $8.7M |
| Diluted EPS | -$0.06 | $0.70 | $0.82 | $0.63 | $3.28 | $1.46 | $14.11 | $0.44 |
| Operating cash flow | $302,000.00 | $21.7M | $14.5M | -$893,000.00 | $30.5M | $24.0M | $22.0M | $2.7M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | 1.2% | 25.4% | 28.9% | 23.9% | 60.1% | 40.9% | 33.2% | 20.2% |
| Net margin | -2.8% | 22.5% | 24.9% | 21.5% | 58.6% | 40.2% | 384.0% | 14.7% |
Company news
Jul 7, 2026
Jul 1, 2026
Jun 16, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-08 | HANNAH ALISON L.· EVP, Chief Medical Officer | Award | 24,400 | $0.00 | $0.00 | filing |
| 2026-06-22 | Ali-Jackson Kamil | Sale | 2,500 | $35.00 | $87,500.00 | filing |
| 2026-06-01 | RODRIGUEZ RAUL R· CEO, President | Tax withholding | 2,424 | $29.86 | $72,380.64 | filing |
| 2026-06-01 | Schorno Dean L· EVP & Chief Financial Officer | Tax withholding | 928 | $29.86 | $27,710.08 | filing |
| 2026-06-01 | Schorno Dean L· EVP & Chief Financial Officer | Option exercise | 2,181 | $12.70 | $27,698.70 | filing |
| 2026-06-01 | Furey Raymond J.· EVP, GC, CCO & Corp Sec | Tax withholding | 877 | $29.86 | $26,187.22 | filing |
| 2026-06-01 | Santos David A· EVP, Chief Commercial Officer | Tax withholding | 874 | $29.86 | $26,097.64 | filing |
| 2026-06-01 | Rojkjaer Lisa· EVP, Chief Medical Officer | Tax withholding | 850 | $29.86 | $25,381.00 | filing |
| 2026-06-01 | Schorno Dean L· EVP & Chief Financial Officer | Option exercise | 1,200 | $18.70 | $22,440.00 | filing |
| 2026-05-26 | Ali-Jackson Kamil | Sale | 2,500 | $29.17 | $72,925.00 | filing |
| 2026-05-15 | HANNAH ALISON L. | Award | 5,750 | $0.00 | $0.00 | filing |
| 2026-05-15 | Wasman Jane | Award | 5,750 | $0.00 | $0.00 | filing |
| 2026-05-15 | MOOS WALTER H | Award | 5,750 | $0.00 | $0.00 | filing |
| 2026-05-15 | MILLER MICHAEL PATRICK | Award | 5,750 | $0.00 | $0.00 | filing |
| 2026-05-15 | LAPOINTE ANTHONY GREGG | Award | 5,750 | $0.00 | $0.00 | filing |
| 2026-05-15 | Frohlich Mark W | Award | 5,750 | $0.00 | $0.00 | filing |
| 2026-05-15 | Ali-Jackson Kamil | Award | 5,750 | $0.00 | $0.00 | filing |
| 2026-02-20 | MOOS WALTER H | Sale | 4,000 | $36.36 | $145,440.00 | filing |
| 2026-02-20 | MOOS WALTER H | Option exercise | 4,000 | $24.00 | $96,000.00 | filing |
| 2026-02-17 | Rojkjaer Lisa· EVP, Chief Medical Officer | Award | 18,894 | $0.00 | $0.00 | filing |
| 2026-02-17 | RODRIGUEZ RAUL R· CEO, President | Award | 53,915 | $0.00 | $0.00 | filing |
| 2026-02-17 | Schorno Dean L· EVP & Chief Financial Officer | Award | 20,636 | $0.00 | $0.00 | filing |
| 2026-02-17 | Santos David A· EVP, Chief Commercial Officer | Award | 19,430 | $0.00 | $0.00 | filing |
| 2026-02-17 | Furey Raymond J.· EVP, GC, CCO & Corp Sec | Award | 19,497 | $0.00 | $0.00 | filing |
| 2026-02-10 | RODRIGUEZ RAUL R· CEO, President | Tax withholding | 7,607 | $34.62 | $263,354.34 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.